LH

Labcorp to Release Q1 2024 Financial Results

Labcorp (NYSE: LH) is set to release its first-quarter financial results for 2024 on April 25. The global leader in laboratory services is expecting to present its performance for the period before the market opens on the said date.

Key figures from the upcoming release will shed light on Labcorp's financial standing and operational performance. The company's more than 67,000 employees have been serving clients in approximately 100 countries and have provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA. Moreover, Labcorp performed more than 600 million tests for patients around the world.

Investors and analysts will be keenly interested in metrics that detail Labcorp's revenue, net income, and earnings per share. Additionally, any changes in operating expenses, margins, and cash flow from the prior period will be closely scrutinized.

The company will also host a conference call and webcast at 9 a.m. ET on the same day to discuss the results in detail, providing an opportunity for stakeholders to gain insights into the factors driving Labcorp's performance in the first quarter of 2024. As a result of these announcements, the company's shares have moved 1.1% on the market, and are now trading at a price of $215.78. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS